Sanjay K. Kakkar
Chief Executive Officer at Tranquis Therapeutics, Inc.
Profile
Sanjay K.
Kakkar currently works at Tranquis Therapeutics, Inc., as President & Chief Executive Officer from 2018.
Dr. Kakkar also formerly worked at Trigen Holdings AG, as Chief Executive Officer from 1997 to 2009, Armetheon, Inc., as Chief Executive Officer, Peptilogics, Inc., as Chief Executive Officer & Director, Novartis Corp., as Product Manager, and Pharmacia, Inc., as Principal.
Dr. Kakkar received his graduate degree from Harvard University, graduate degree from Imperial College London, and doctorate degree from King's College London.
Sanjay K. Kakkar active positions
| Companies | Position | Start |
|---|---|---|
Tranquis Therapeutics, Inc.
 Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | Chief Executive Officer | 31/12/2017 |
Former positions of Sanjay K. Kakkar
| Companies | Position | End |
|---|---|---|
Trigen Holdings AG
 Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | President | 14/12/2009 |
Peptilogics, Inc.
 Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | Chief Executive Officer | - |
Armetheon, Inc.
 Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Chief Executive Officer | - |
| Pharmacia, Inc. | Corporate Officer/Principal | - |
Novartis Corp.
 Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Corporate Officer/Principal | - |
Training of Sanjay K. Kakkar
| Harvard University | Graduate Degree |
| King's College London | Doctorate Degree |
| Imperial College London | Graduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 6 |
|---|---|
Trigen Holdings AG
Trigen Holdings AG Miscellaneous Commercial ServicesCommercial Services Trigen Holdings AG develops drugs focusing on thrombosis and vascular dysfunction. Its product pipeline includes clinical stage candidates, TGN 255, TGN 167 and PR-15. The company has offices in London. Trigen Holdings was founded in 2005 and is headquartered in Martinsried, Germany. | Commercial Services |
Novartis Corp.
Novartis Corp. Pharmaceuticals: MajorHealth Technology Novartis Corp. manufactures pharmaceuticals, vaccines, consumer health, generics, eye care and animal health products. It manufactures drugs for oncology, hypertension, diabetes, cancer and cardiovascular diseases. The company was founded on November 15, 1996 and is headquartered in New York, NY. | Health Technology |
| Pharmacia, Inc. | |
Armetheon, Inc.
Armetheon, Inc. Pharmaceuticals: MajorHealth Technology Armetheon, Inc. engages in medical development. It specializes in thrombosis and cardiac arrhythmias. The company was founded by Pascal J. Druzgala, Muralitharan Ken Kengatharan and Peter G. Milner in 2011 and is headquartered in Milpitas, CA. | Health Technology |
Peptilogics, Inc.
Peptilogics, Inc. Miscellaneous Commercial ServicesCommercial Services Peptilogics, Inc. operates as an early-stage biotechnology company, that develops a new class of antibiotics with a novel mechanism of action derived from their eCAP (engineered cationic antibiotic peptide) platform for the treatment of multidrug-resistant infections. Its platform has the potential to produce antibiotics with broad-spectrum activity with low risk of generating resistance, due to the unique mechanism of action involving the targeted disruption of bacterial membranes. The company was founded by Jonathan Steckbeck and is headquartered in Pittsburgh, PA. | Commercial Services |
Tranquis Therapeutics, Inc.
Tranquis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Tranquis Therapeutics, Inc. discovers and develops novel immuno-therapeutics for neurological diseases. It offers treatment for central nervous system (CNS) disorders, including Amyotrophic Lateral Sclerosis, Parkinson 's disease, Alzheimer?s Disease, and age-related neuropathology. The company was founded by Chih-Ping Liu and Khoa D. Nguyen in June 2016 and is headquartered in Menlo Park, CA. | Health Technology |
- Stock Market
- Insiders
- Sanjay K. Kakkar
